Top APAC (Ex-China) Investment Worthy Healthcare Companies Using Smartkarma’s Smart Score Screener
We have screened APAC (ex-China) healthcare companies with market cap≥$800M using Smartkarma’s Smart Score and picked up 2 investable ideas by...
635 Views
Primer: Kaken Pharmaceutical (4521 JP) - Aug 2026
Kaken Pharmaceutical is an R&D-driven specialty pharmaceutical company with established strengths in dermatology and orthopedics, deriving...
92 Views
Kaken Pharma (4521 JP): Growth Pangs Continue in 9MFY26, Guidance Marginally Revised
Kaken Pharmaceutical (4521 JP) reports underwhelming earnings in 9MFY26. Company needs strong revenue driver to combat challenges from drug price...
173 Views
Kaken Pharma (4521 JP): Bleaker FY26 Ahead, Growth Pangs to Continue for Now
Kaken Pharmaceutical (4521 JP) reports underwhelming H1FY26 earnings with significant drops in revenue and profit. Needs strong revenue driver to...
312 Views
APAC Healthcare Weekly (August 2) – CSPC, Hengrui, Otsuka, Nippon Shinyaku, PharmaEssnetia, Cipla
Hengrui got NMPA approval for long-acting insulin. FDA approves Otsuka’s new CNS drug. Pharmaessentia announced positive topline result from Phase...
136 Views